治愈复发性卵巢癌:一个多中心的回顾性研究
Masahiro Sumitomo1,2, Yasushi Kotani1, Kosuke Murakami1
1Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan.
Cancers
|September 27, 2025
概括
大约10%的复发性卵巢癌患者达到4年无病生存期 (DFS),并被认为是治愈的. 在这项研究中,确定了治愈病例的特征和治愈标准.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 癌症研究 癌症研究
背景情况:
- 再发性卵巢癌的预后不好,治疗潜力有限.
- 确定治愈标准和治愈患者的特征至关重要.
研究的目的:
- 确定治疗复发性卵巢癌的标准.
- 为了确定与治愈相关的患者和瘤特征.
主要方法:
- 来自大学和社区医院的复发性卵巢癌病例的分析.
- 评估完全缓解 (CR) 和没有疾病证据 (NED) 状态.
- 在瘤样本中包括BRCA1/2突变分析.
主要成果:
- 13%的复发病例没有疾病的证据 (NED).
- 治愈的病例 (NED) 显示出较低的初始,更长的无病生存期 (DFS),单独的病变,以及较高的二次脱皮手术率.
- 作为完全缓解 (CR) 病例中治愈的标准,建立了4年的DFS.
- 在5/11例高度血清癌 (HGSC) 病例中发现了BRCA致病变体,这些病例实现了4年的DFS.
结论:
- 大约10%的复发性卵巢癌患者达到4年的DFS,这表明治愈的可能性很高.
- 非HGSC病例的治愈独立于致病性BRCA变异.
- 这项研究提供了关于复发性卵巢癌的可治疗性和预后因素的见解.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648


